Avalyn Pharma Inc. AVLN
27.78 USD +1.11 (+4.16%)
Nov 6, 2026, 10:26 AM EST
26.13 Day range 27.78
22.24 52-week range 40.17
- YTD
- -5.80%
- 1 year
- -5.80%
Held by funds
67 US ETFs and mutual funds hold AVLN · largest positions
Ownership
Held by insiders 0.00%
Held by institutions 104.08%
Float held by institutions 104.08%
Institutions 147
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.16% | 5,835,259 | 155.51M | Jun 29, 2026 |
| Novo Holdings A/S | 8.76% | 3,883,289 | 103.49M | Jun 29, 2026 |
| SR One Capital Management, LP | 7.46% | 3,308,649 | 88.18M | Jun 29, 2026 |
| Perceptive Advisors Llc | 6.03% | 2,675,296 | 71.30M | Jun 29, 2026 |
| Montanova Capital LLC | 5.65% | 2,503,109 | 66.71M | Jun 29, 2026 |
| NVP Associates, LLC | 5.12% | 2,268,404 | 60.45M | Jun 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.78% | 1,231,620 | 32.82M | Jul 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 1.41% | 627,190 | 16.71M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.21% | 534,440 | 14.24M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.05% | 466,565 | 12.43M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.94% | 415,610 | 11.08M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.89% | 396,069 | 10.56M | Jun 29, 2026 |
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARROLL JILL | Director | Purchase | Apr 30, 2026 | 0 |
| FMR LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 30, 2026 | 0 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 30, 2026 | 3,883,290 |
| SR ONE CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 30, 2026 | 0 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 30, 2026 | 1,275,490 |